Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
about
Belimumab for systemic lupus erythematosusThe intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the gamesThe current status of targeting BAFF/BLyS for autoimmune diseasesSLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorderCurrent and emerging treatment options in the management of lupusKey issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implicationsB-cell survival factors in autoimmune rheumatic disordersLinking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosusCellular targeting in autoimmunityRole of type I interferons in the activation of autoreactive B cellsEffect of TACI signaling on humoral immunity and autoimmune diseasesThe effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responsesPiecing together the humoral and cellular mechanisms of immune thrombocytopeniaFollicular Helper T Cells in Systemic Lupus Erythematosus: Why Should They Be Considered as Interesting Therapeutic Targets?Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus ErythematosusB lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseasesA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusA therapeutic role for BLyS antagonistsA soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeysAPRIL-deficient mice have normal immune system developmentBaseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels.Antibodies as therapeutic agents: vive la renaissance!High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura.BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura.Preclinical support for combination therapy in the treatment of autoimmunity with atacicept.Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.Direct B-cell stimulation by peripheral blood monocyte-derived dendritic cells in idiopathic thrombocytopenic purpura patients.Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells.Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and futureSystems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment.B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers.Pathways leading to an immunological disease: systemic lupus erythematosus.B cell activating factor (BAFF) and T cells cooperate to breach B cell tolerance in lupus-prone New Zealand Black (NZB) miceEfficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritisB cell abnormalities in systemic lupus erythematosusComparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation.The strength of the antibody response to the nematode Ascaris lumbricoides inversely correlates with levels of B-Cell Activating Factor (BAFF).Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF
P2860
Q24201547-D2FF7B8D-5398-4DBA-A9E4-79A736481DBAQ24683018-CCAB218E-831D-4F89-B317-E66C07E12523Q24796930-4B2CC0DC-8524-4B33-8F72-B087FD66AF49Q24804613-0BA2E26A-C67A-4A36-9058-8D6B8903EC30Q26741266-59E5C5E6-559F-411E-9CD9-CB8BD8517958Q26775756-8E3C64A5-17E2-4E55-AD35-8B6039509D51Q26796484-572E17EC-8011-4A67-959E-06C0A3AC1BA8Q26822662-1ADA110D-14C5-4139-AA83-3535E85B7758Q26824580-8B2A23C2-238B-404E-8723-34F3FCED34AFQ26858821-57AFB518-0C4E-41D3-8367-08CFC7DDD280Q26995571-D724ABC6-552B-461E-A47B-A2294DCBBD91Q27022645-9B249D4B-F905-4597-BB69-7231BBB0A859Q27024841-B23BAC3A-0ECD-4C8E-ACE8-830D9FE7207AQ28067781-F11BF70B-BA95-4EB2-A9CF-82F6114A58D2Q28088753-94B48BF9-DDDB-41CC-9BA8-855D733C31EEQ28208717-AFFCE7FF-3EF8-48A6-A6BB-AC5A6BE181D1Q28254310-3FE491BD-9E55-4E6C-80D3-24BD5AC580CBQ28269809-6D0CDD90-4748-48C7-8A8B-B46EC87D1E4EQ28293722-2E1AE582-3ADE-4321-BEC5-A6FECBE40787Q28511017-37110841-D275-4C0B-A321-4AB901D2E5D0Q30645037-310B31AB-1439-4E57-A780-45E33D69B0A7Q31087724-F6554AB9-7345-42E1-8FA9-DC6605152DFDQ33193524-5690E864-8959-426D-ABE8-E7AB0331DDE4Q33373525-A2C70BDC-A4C8-4180-9ADE-66B269981D01Q33381985-19DEEC37-4E24-42CB-AFEC-6746A4DB4E8DQ33382933-C70319AE-BABC-4625-85AA-922D34600409Q33385389-538048C4-25EA-4148-9D1F-DBCC1A62C6BFQ33390753-82FACD1D-F989-4A1A-8016-8A2A565CE814Q33440567-FAA28109-554C-4A16-B519-E0A572DC73C2Q33601679-16599151-044F-416F-AF5C-C6142FC2D251Q33608479-809B71F3-4BE3-45E9-97BC-5291B8092932Q33616360-C76FB1EF-4F94-4FD4-921A-F3D9C0E9FDB1Q33620555-6B9F983C-A043-4C3A-8F8A-A171FF68D4C9Q33641498-A7EB944A-048C-497D-847F-06CF2FE6F2D4Q33698040-EAA18A31-6AF0-422C-8FB9-7C4A50F48184Q33706318-9BA8972A-D671-489D-AACF-F2AC422ED705Q33708833-28DB8732-C3B2-402A-AEC4-FD5956CF286AQ33752808-CDCB76EA-C758-483F-BA19-9EBE7CD05873Q33792424-8F79BA81-7719-4154-A598-21866978FBE7Q33960050-CD591DA4-4677-4970-BD15-A0924FABF0E3
P2860
Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Elevated serum B lymphocyte st ...... mune-based rheumatic diseases.
@ast
Elevated serum B lymphocyte st ...... mune-based rheumatic diseases.
@en
type
label
Elevated serum B lymphocyte st ...... mune-based rheumatic diseases.
@ast
Elevated serum B lymphocyte st ...... mune-based rheumatic diseases.
@en
prefLabel
Elevated serum B lymphocyte st ...... mune-based rheumatic diseases.
@ast
Elevated serum B lymphocyte st ...... mune-based rheumatic diseases.
@en
P2093
P1476
Elevated serum B lymphocyte st ...... mune-based rheumatic diseases.
@en
P2093
P304
P356
10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S
P577
2001-06-01T00:00:00Z